Učitavanje...
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
BACKGROUND: Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) and provided a significantly prolonged progression-free survival compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring rearrangements of the ALK gene....
Spremljeno u:
| Izdano u: | Surg Case Rep |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer Berlin Heidelberg
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845085/ https://ncbi.nlm.nih.gov/pubmed/29524063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40792-018-0430-7 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|